Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people

Objectives To study the association between exposures to glucose-lowering therapy and risk of cancer using the nationwide administrative registers in Denmark. Design Nationwide cohort study. Setting All hospitals in Denmark. Participants All individuals aged ≥35 years in 1998–2009 who were naive to glucose-lowering treatment and had no history of cancer. Primary measures outcomes: first cancer diagnosis between 1998 and 2009. The RR of cancer as dependent on exposure to individual glucose-lowering agents was assessed by multivariable Poisson regression models. Results Of 159 894 patients that initiated treatment with glucose-lowering agents, 12 789 developed cancer, incidence rate 17.4/1000 person-years. Of the remaining 3 447 904 individuals not using glucose-lowering agents, 293 878 developed cancer, incidence rate 7.9/1000 person-years. Use of different types of glucose-lowering agents including human insulin, insulin analogues, as well as sulfonylureas were associated with a quantitatively similar and significantly increased RR of cancer of 1.2–1.3 compared with unexposed individuals after multivariable adjustment. For the majority of agents, the authors identified the highest RR of cancer during the first 30 treatment days with a subsequent decline of risk approaching the cancer risk of the background population only 6–12 months after initiation of treatments. Conclusions Use of most glucose-lowering agents including sulfonylureas was associated with a comparable increased risk of cancer shortly after initiation of treatment and subsequently a decline to the risk of the background population. This suggests that the relation is not causal.

[1]  S. Friis,et al.  Cancer occurrence in Danish diabetic patients: duration and insulin effects , 2012, Diabetologia.

[2]  Marianne Lundkjær Gjerstorff,et al.  The Danish Cancer Registry , 2011, Scandinavian journal of public health.

[3]  K. Borch-Johnsen,et al.  The National Diabetes Register , 2011, Scandinavian journal of public health.

[4]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[5]  A. Vaag,et al.  Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study , 2010, Diabetologia.

[6]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[7]  B. Gersh Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2010 .

[8]  L. Køber,et al.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.

[9]  H. Colhoun,et al.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[10]  U. Smith,et al.  Does diabetes therapy influence the risk of cancer? , 2009, Diabetologia.

[11]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[12]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[13]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[14]  L. Køber,et al.  Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study , 2009, Clinical pharmacology and therapeutics.

[15]  H. Werner,et al.  Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activities in cultured cancer cells , 2009, Diabetes/metabolism research and reviews.

[16]  Jeffrey A. Johnson,et al.  Prospective Study of Hyperglycemia and Cancer Risk , 2007, Diabetes Care.

[17]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[18]  J. Samet,et al.  Fasting serum glucose level and cancer risk in Korean men and women. , 2005, JAMA.

[19]  J. Watkins,et al.  Diabetes, oxidative stress, and antioxidants: A review , 2003, Journal of biochemical and molecular toxicology.

[20]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[21]  H. Sørensen,et al.  The Danish prescription registries. , 1997, Danish medical bulletin.

[22]  J. Poulson The management of diabetes in patients with advanced cancer. , 1997, Journal of pain and symptom management.

[23]  V. Macaulay,et al.  Insulin-like growth factors and cancer. , 1992, British Journal of Cancer.

[24]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[25]  J. Halter,et al.  Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. , 1984, The American journal of physiology.